Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluocinolone acetonide - Alimera/EyePoint Pharmaceuticals

Drug Profile

Fluocinolone acetonide - Alimera/EyePoint Pharmaceuticals

Alternative Names: DF-277; FAI insert; Fluocinolone; Fluocinolone acetonide intravitreal implant; Fluocinolone acetonide intravitreal insert; Fluocinolone acetonide micro-insert intravitreous implant - Alimera/EyePoint Pharmaceuticals; Iluvien; Injectable micro-insert - Alimera Sciences/EyePoint Pharmaceuticals; Medidur implant; Medidur-FA; NSC-92339; Ophthalmic implant - Alimera Sciences/EyePoint Pharmaceuticals; OT-401; OT-703; YUTIQ; YUTIQ50

Latest Information Update: 13 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pSivida Inc
  • Developer Alimera Sciences; EyePoint Pharmaceuticals; Horus Pharma; Hospital for Special Surgery; Johns Hopkins University; Ocumension Therapeutics; pSivida Inc; Specialised Therapeutics Australia
  • Class Anti-inflammatories; Antipruritics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Pregnadienes; Small molecules; Vasoconstrictors
  • Mechanism of Action Glucocorticoid receptor agonists; Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetic macular oedema; Uveitis
  • Phase II Retinal vascular occlusion; Wet age-related macular degeneration
  • No development reported Osteoarthritis

Most Recent Events

  • 08 Feb 2024 NICE issues final draft guidance recommending fluocinolone acetonide for Diabetic macular edema
  • 08 Sep 2023 EyePoint Pharmaceuticals terminates a phase III trial in Uveitis (Treatment-experienced) in USA (Intravitreous) (NCT05070728)
  • 18 May 2023 Fluocinolone acetonide licensed to Alimera Sciences outside of China, Hong Kong, Taiwan, Macau and Southeast Asia for eye disorders
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top